Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Dri Healthcare Trust T.DHT.UN

Alternate Symbol(s):  DHTRF

Healthcare Biotechnology
DRI Healthcare Trust is an open-ended trust that provides unitholders with differentiated exposure to the anticipated growth in the global pharmaceuticals and biotechnology markets. Its business model is focused on managing and growing a diversified portfolio of pharmaceutical royalties to deliver attractive growth in cash royalty receipts over the long term. Geographically, it has a presence in the United States; European Union; Japan, and Rest of the world.


TSX:DHT.UN - Post by User

Dri Healthcare Trust
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Post by PressReleaseon Nov 28, 2022 7:30am
84 Views
Post# 35133128

New Press Release - DRI Healthcare Trust Announces Acquisition of a Royalty Interest in the Worldwide Sales of Xenpozyme&#xAE; (olipudase alfa) for the Treatment of Acid Sphingomyelinase Deficiency

New Press Release - DRI Healthcare Trust Announces Acquisition of a Royalty Interest in the Worldwide Sales of Xenpozyme&#xAE; (olipudase alfa) for the Treatment of Acid Sphingomyelinase Deficiency
– Transaction adds another innovative rare disease therapy to DRI's expanding portfolio –– Deal structure offers risk sharing with milestone payments for positive performance –– Long-term patent-protected exclusivity extends DRI's cash flows –TORONTO, Nov. 28, 2022 /CNW/ - DRI Healthcare Trust...read article.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities